The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Motif Bio Shares Up As It Moves Towards Iclaprim Clinical Trials

Mon, 01st Jun 2015 07:23

LONDON (Alliance News) - Motif Bio PLC saw its shares rise early Monday after it said its Motif BioSciences Inc subsidiary has signed letters of intend and interim agreements with an unnamed global clinical research organisation, the first step towards getting Motif Bio's Iclaprim developmental antibiotic through key clinical trials.

The antiobiotic developer said that under the terms of the interim agreements, the clinical research organisation will start preparing for two Phase III randomised, double-blind, multi-centre clinical trials to evaluate the efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive pathogens.

Iclaprim is a broad-spectrum antibiotic designed to be effective against multi-drug resistant bacteria.

Under the terms of the interim agreements, Motif will invest over USD950,000. The two parties are now negotiating a formal agreement on the basis of the letters of intent for the conduct of the two studies.

Motif didn't name the research organisation, but said it is "one of the world's top five providers of Phase I-IV clinical trial management services and to date, has contributed to the development of all of the top 50 prescription medicines on the market. The CRO has unique insights into infectious disease clinical trials with over 17,000 patients in more than 150 studies."

Motif Bio shares were up 15.5% at 50.11 pence early Monday, one of the best-performing stocks in the AIM All-Share index.

By Steve McGrath; stevemcgrath@alliancenews.com; @stevemcgrath1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
14 Jun 2021 20:33

TRADING UPDATES: Motif Bio takeover called off; Yamana buys at Wasamac

TRADING UPDATES: Motif Bio takeover called off; Yamana buys at Wasamac

Read more
26 May 2021 21:28

IN BRIEF: Motif Bio expects market capitalisation of GBP16.2 million

IN BRIEF: Motif Bio expects market capitalisation of GBP16.2 million

Read more
26 May 2021 18:18

TRADING UPDATES: AVI Global sees strong results; Finsbury Food rebound

TRADING UPDATES: AVI Global sees strong results; Finsbury Food rebound

Read more
10 May 2021 15:52

IN BRIEF: Motif Bio 2020 loss narrows due to impairment in prior year

IN BRIEF: Motif Bio 2020 loss narrows due to impairment in prior year

Read more
29 Mar 2021 14:25

IN BRIEF: Motif Bio progresses reverse takeover, expects AIM return

IN BRIEF: Motif Bio progresses reverse takeover, expects AIM return

Read more
26 Feb 2021 20:20

LONDON TRADING UPDATES: Motif Bio Says Orange Avenue Buys Subsidiary

LONDON TRADING UPDATES: Motif Bio Says Orange Avenue Buys Subsidiary

Read more
27 Jan 2021 14:37

IN BRIEF: Motif Bio Making Progress On UK Drug Development Firm Buy

IN BRIEF: Motif Bio Making Progress On UK Drug Development Firm Buy

Read more
5 Jan 2021 15:04

IN BRIEF: Motif Bio Advancing Process To Complete Reverse Takeover

IN BRIEF: Motif Bio Advancing Process To Complete Reverse Takeover

Read more
12 Oct 2020 11:50

Cash Shell Motif Bio Swings To Interim Loss On Derivative Liabilities

Cash Shell Motif Bio Swings To Interim Loss On Derivative Liabilities

Read more
23 Sep 2020 16:13

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
1 Sep 2020 14:08

IN BRIEF: Motif Bio Annual Pretax Loss Narrows Amid Takeover Hopes

IN BRIEF: Motif Bio Annual Pretax Loss Narrows Amid Takeover Hopes

Read more
29 Jul 2020 15:39

IN BRIEF: Motif Bio Shares Suspended; Still Hopes For Reverse Takeover

IN BRIEF: Motif Bio Shares Suspended; Still Hopes For Reverse Takeover

Read more
29 Jul 2020 09:59

Motif Bio shares suspended from trading

(Sharecast News) - Pharmaceutical company Motif Bio saw its shares suspended from trading on Wednesday in order to satisfy AIM rules.

Read more
23 Jun 2020 08:48

CORRECT: Motif Bio Delays 2019 Results As Faces AIM Takeover Deadline

CORRECT: Motif Bio Delays 2019 Results As Faces AIM Takeover Deadline

Read more
22 Jun 2020 14:14

IN BRIEF: Motif Bio Delays 2019 Results As Faces AIM Takeover Deadline

IN BRIEF: Motif Bio Delays 2019 Results As Faces AIM Takeover Deadline

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.